JP2024534502A - オリゴヌクレオチドのインビボ送達に使用するための2’-アルキル又は3’-アルキル修飾リボース誘導体 - Google Patents

オリゴヌクレオチドのインビボ送達に使用するための2’-アルキル又は3’-アルキル修飾リボース誘導体 Download PDF

Info

Publication number
JP2024534502A
JP2024534502A JP2024517430A JP2024517430A JP2024534502A JP 2024534502 A JP2024534502 A JP 2024534502A JP 2024517430 A JP2024517430 A JP 2024517430A JP 2024517430 A JP2024517430 A JP 2024517430A JP 2024534502 A JP2024534502 A JP 2024534502A
Authority
JP
Japan
Prior art keywords
scaffold
compound
conjugate
optionally substituted
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024517430A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534502A5 (cg-RX-API-DMAC7.html
Inventor
ワン ウェイミン
ツァイ シアオチョアン
Original Assignee
セーンジーン バイオ ユーエスエー インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セーンジーン バイオ ユーエスエー インコーポレイティド filed Critical セーンジーン バイオ ユーエスエー インコーポレイティド
Publication of JP2024534502A publication Critical patent/JP2024534502A/ja
Publication of JP2024534502A5 publication Critical patent/JP2024534502A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2024517430A 2021-09-22 2022-09-22 オリゴヌクレオチドのインビボ送達に使用するための2’-アルキル又は3’-アルキル修飾リボース誘導体 Pending JP2024534502A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163246870P 2021-09-22 2021-09-22
US63/246,870 2021-09-22
PCT/US2022/044377 WO2023049258A1 (en) 2021-09-22 2022-09-22 2'-alkyl or 3'- alkyl modified ribose derivatives for use in the in-vivo delivery of oligonucleotides

Publications (2)

Publication Number Publication Date
JP2024534502A true JP2024534502A (ja) 2024-09-20
JP2024534502A5 JP2024534502A5 (cg-RX-API-DMAC7.html) 2025-09-30

Family

ID=84053050

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024517430A Pending JP2024534502A (ja) 2021-09-22 2022-09-22 オリゴヌクレオチドのインビボ送達に使用するための2’-アルキル又は3’-アルキル修飾リボース誘導体

Country Status (9)

Country Link
US (1) US20230241224A1 (cg-RX-API-DMAC7.html)
EP (1) EP4405368A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024534502A (cg-RX-API-DMAC7.html)
KR (1) KR20240082361A (cg-RX-API-DMAC7.html)
CN (1) CN118076619A (cg-RX-API-DMAC7.html)
AU (1) AU2022352676A1 (cg-RX-API-DMAC7.html)
CA (1) CA3233113A1 (cg-RX-API-DMAC7.html)
IL (1) IL311486A (cg-RX-API-DMAC7.html)
WO (1) WO2023049258A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4705312A1 (en) * 2023-05-03 2026-03-11 Sanegene Bio USA Inc. Lipid-based conjugates for systemic, central nervous system, peripheral nervous system, and ocular delivery
AU2024301344A1 (en) * 2023-07-24 2026-01-29 Sanegene Bio Usa Inc. Lipid-based enhancement agent for rna delivery and therapy
CN116854754B (zh) 2023-09-01 2023-12-12 北京悦康科创医药科技股份有限公司 一种含有核糖环或其衍生结构的GalNAc化合物及其寡核苷酸缀合物
WO2025144872A2 (en) * 2023-12-29 2025-07-03 Adarx Pharmaceuticals, Inc. Nucleoside-derived lipids for drug delivery
WO2026041067A2 (en) 2024-08-20 2026-02-26 Sanegene Bio Usa Inc. Small interfering rna targeting myostatin (mstn) and uses thereof
WO2026046411A1 (en) 2024-09-02 2026-03-05 Sanegene Bio Usa Inc. Small interfering rna targeting plasminogen (plg) and uses thereof
WO2026092658A2 (en) 2024-10-31 2026-05-07 Sanegene Bio Usa Inc. Small interfering rna targeting amyloid beta precursor protein (app) and uses thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014515023A (ja) * 2011-04-13 2014-06-26 メルク・シャープ・アンド・ドーム・コーポレーション 2’−置換ヌクレオシド誘導体およびウイルス疾患の処置のためのその使用方法
JP2016529230A (ja) * 2013-07-11 2016-09-23 アルニラム ファーマスーティカルズ インコーポレイテッドAlnylam Pharmaceuticals, Inc. オリゴヌクレオチド−リガンドコンジュゲートおよびそれらの調製方法
CN106366146A (zh) * 2015-07-13 2017-02-01 中科云和(北京)生物医药科技有限公司 2’-双烷基取代的核苷类似物及用途
US20170044205A1 (en) * 2014-04-16 2017-02-16 Idenix Pharmaceuticals Llc 3'-substituted methyl or alkynyl nucleosides nucleotides for the treatment of hcv
JP2017512774A (ja) * 2014-03-16 2017-05-25 ミラゲン セラピューティクス, インコーポレイテッド 二環式ヌクレオシドの合成
JP2018500027A (ja) * 2014-12-15 2018-01-11 ダイセルナ ファーマシューティカルズ, インコーポレイテッドDicerna Pharmaceuticals, Inc. リガンド修飾二本鎖核酸
JP2018522914A (ja) * 2015-08-13 2018-08-16 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Stingアゴニストとしての環状ジヌクレオチド化合物
WO2021067744A1 (en) * 2019-10-02 2021-04-08 Dicerna Pharmaceuticals, Inc. Chemical modifications of small interfering rna with minimal fluorine content

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
CA1340323C (en) 1988-09-20 1999-01-19 Arnold E. Hampel Rna catalyst for cleaving specific rna sequences
GB8822492D0 (en) 1988-09-24 1988-10-26 Considine J Apparatus for removing tumours from hollow organs of body
CA2039718C (en) 1989-08-31 2003-02-25 John J. Rossi Chimeric dna-rna catalytic sequences
US6365730B1 (en) 1990-06-19 2002-04-02 Gene Shears Pty. Limited DNA-Armed ribozymes and minizymes
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
AU649074B2 (en) 1990-10-12 1994-05-12 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Modified ribozymes
DE4216134A1 (de) 1991-06-20 1992-12-24 Europ Lab Molekularbiolog Synthetische katalytische oligonukleotidstrukturen
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
CA2135646A1 (en) 1992-05-11 1993-11-25 Kenneth G. Draper Method and reagent for inhibiting viral replication
JPH07509133A (ja) 1992-07-17 1995-10-12 リボザイム・ファーマシューティカルズ・インコーポレイテッド 動物疾患の処置のための方法および剤
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5591317A (en) 1994-02-16 1997-01-07 Pitts, Jr.; M. Michael Electrostatic device for water treatment
US5631359A (en) 1994-10-11 1997-05-20 Ribozyme Pharmaceuticals, Inc. Hairpin ribozymes
AU3889595A (en) 1994-10-05 1996-05-02 Amgen, Inc. Method for inhibiting smooth muscle cell proliferation and oligonucleotides for use therein
US5783683A (en) 1995-01-10 1998-07-21 Genta Inc. Antisense oligonucleotides which reduce expression of the FGFRI gene
US5747470A (en) 1995-06-07 1998-05-05 Gen-Probe Incorporated Method for inhibiting cellular proliferation using antisense oligonucleotides to gp130 mRNA
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
CA2518475C (en) 2003-03-07 2014-12-23 Alnylam Pharmaceuticals, Inc. Irna agents comprising asymmetrical modifications
EP2669377A3 (en) 2003-04-17 2015-10-14 Alnylam Pharmaceuticals Inc. Modified iRNA agents
AU2006279906B2 (en) 2005-08-10 2012-05-10 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
EP2229186A2 (en) 2007-12-04 2010-09-22 Alnylam Pharmaceuticals Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
RU2582235C2 (ru) 2010-12-29 2016-04-20 Ф.Хоффманн-Ля Рош Аг Низкомолекулярные конъюгаты для внутриклеточной доставки нуклеиновых кислот
US8577565B2 (en) 2011-12-16 2013-11-05 GM Global Technology Operations LLC Limiting branch pressure to a solenoid valve in a fluid circuit
TWI912633B (zh) 2016-06-06 2026-01-21 美商愛羅海德製藥公司 5'-環-磷酸修飾之核苷酸
MX2019002075A (es) 2016-08-23 2019-07-01 Dicerna Pharmaceuticals Inc Composiciones que comprenden oligonucleotidos modificados reversiblemente, y sus usos.
WO2018045317A1 (en) 2016-09-02 2018-03-08 Dicerna Pharmaceuticals, Inc. 4'-phosphate analogs and oligonucleotides comprising the same

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014515023A (ja) * 2011-04-13 2014-06-26 メルク・シャープ・アンド・ドーム・コーポレーション 2’−置換ヌクレオシド誘導体およびウイルス疾患の処置のためのその使用方法
JP2016529230A (ja) * 2013-07-11 2016-09-23 アルニラム ファーマスーティカルズ インコーポレイテッドAlnylam Pharmaceuticals, Inc. オリゴヌクレオチド−リガンドコンジュゲートおよびそれらの調製方法
JP2017512774A (ja) * 2014-03-16 2017-05-25 ミラゲン セラピューティクス, インコーポレイテッド 二環式ヌクレオシドの合成
US20170044205A1 (en) * 2014-04-16 2017-02-16 Idenix Pharmaceuticals Llc 3'-substituted methyl or alkynyl nucleosides nucleotides for the treatment of hcv
JP2018500027A (ja) * 2014-12-15 2018-01-11 ダイセルナ ファーマシューティカルズ, インコーポレイテッドDicerna Pharmaceuticals, Inc. リガンド修飾二本鎖核酸
CN106366146A (zh) * 2015-07-13 2017-02-01 中科云和(北京)生物医药科技有限公司 2’-双烷基取代的核苷类似物及用途
JP2018522914A (ja) * 2015-08-13 2018-08-16 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Stingアゴニストとしての環状ジヌクレオチド化合物
WO2021067744A1 (en) * 2019-10-02 2021-04-08 Dicerna Pharmaceuticals, Inc. Chemical modifications of small interfering rna with minimal fluorine content

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROSENTHAL, A. ET AL.: "Branched-chain N-sugar nucleosides. 2. Nucleosides of 3-C-cyanomethyl, carboxamidomethyl, and N,N-", JOURNAL OF ORGANIC CHEMISTRY, vol. 38, no. 2, JPN6026023586, 1973, pages 198 - 201, ISSN: 0005881136 *

Also Published As

Publication number Publication date
WO2023049258A1 (en) 2023-03-30
CN118076619A (zh) 2024-05-24
CA3233113A1 (en) 2023-03-30
KR20240082361A (ko) 2024-06-10
AU2022352676A1 (en) 2024-03-14
EP4405368A1 (en) 2024-07-31
US20230241224A1 (en) 2023-08-03
IL311486A (en) 2024-05-01

Similar Documents

Publication Publication Date Title
JP7842850B2 (ja) 1’-アルキル修飾リボース誘導体及び使用方法
US20230346819A1 (en) 5'-modified carbocyclic ribonucleotide derivatives and methods of use
KR20240082361A (ko) 올리고뉴클레오티드의 생체내 전달에 사용하기 위한 2'-알킬 또는 3'-알킬 변형된 리보스 유도체
JP2024542929A (ja) ポリヒドロキシル化されたシクロペンタン誘導体及び使用方法
KR20260005960A (ko) 전신, 중추 신경계, 말초 신경계, 및 안구 전달을 위한 지질 기반 접합체
JP2025541956A (ja) Rna送達及び治療のためのヌクレオチド系増強剤
AU2024301344A1 (en) Lipid-based enhancement agent for rna delivery and therapy
WO2026102144A2 (en) Oligonucleotide conjugates of phosphocholine lipid derivatives
HK40123279A (en) Nucleotide-based enhancement agent for rna delivery and therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250919

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260609

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260804